ALG 072571
Alternative Names: ALG-072571Latest Information Update: 30 May 2025
At a glance
- Originator Aligos Therapeutics
- Class Antivirals; Small interfering RNA
- Mechanism of Action Programmed cell death 1 receptor expression inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hepatitis B
Most Recent Events
- 30 May 2025 Discontinued - Preclinical for Hepatitis B in USA (SC) prior to May 2025 (Aligos Therapeutics pipeline, May 2025)
- 16 Aug 2023 Pharmacodynamics data from a preclinical trial in Hepatitis B presented at the European Association for the Study of the Liver Congress (EASL-2023)
- 21 Jun 2023 Preclinical trials in Hepatitis B in USA (SC)